ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion-Reference-Cited by-同舟云学术

ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion

Published:2024-04 Issue:9 Volume:187 Page:2305-2323.e33
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Deng Shouyan,Zhang Yibo,Wang Huanbin,Liang Wenhua,Xie Lu,Li Ning,Fang Yuan,Wang Yiting,Liu Jiayang,Chi Hao,Sun Yufan,Ye Rui,Shan Lishen,Shi Jiawei,Shen Zan,Wang Yonggang,Wang Shuhang,Brosseau Jean-Philippe,Wang Feng,Liu Grace,Quan Yingfei,Xu Jie^ORCID

Publisher

Elsevier BV

Reference75 articles.

1. Immune checkpoint therapy-current perspectives and future directions;Sharma;Cell,2023

2. Immune checkpoint inhibitors in melanoma;Carlino;Lancet,2021

3. PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer;Cercek;N. Engl. J. Med.,2022

4. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer;Mirza;N. Engl. J. Med.,2023

5. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade;Morad;Cell,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Circ_0001947 encapsulated by small extracellular vesicles promotes gastric cancer progression and anti-PD-1 resistance by modulating CD8+ T cell exhaustion;Journal of Nanobiotechnology;2024-09-14

2. A comprehensive pan-cancer analysis revealing the role of ITPRIPL1 as a prognostic and immunological biomarker;Frontiers in Molecular Biosciences;2024-08-15

3. Causal Effects and Immune Cell Mediators of Prescription Analgesic Use and Risk of Liver Cancer and Precancerosis in European Population: A Mendelian Randomization Study;Biomedicines;2024-07-11